newsfilter
← Latest News
Business Wire·

Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial Results

ZTALMY® (ganaxolone) Q1 2024 net product revenue of $7.5 million representing strong growth of 125% versus Q1 2023 Increased full year 2024 projected U.S. ZTALMY net product revenues to between $33 and $35